With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...

TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...

(Web Desk) - The harmful effects of air pollution on health, including an increased risk of cancer, have been well-documented ...

A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.

“Head and neck squamous cell carcinoma remains a deadly disease with limited treatment options,” added Dr. Le Tourneau. “With its strong clinical outcomes across a large dataset of patients, ...

Application error: a client-side exception has occurred (see the browser console for more information).

Compared to normal tissues, where the expression of ULBP2/5/6 protein is restricted, in non-small-cell lung cancer (NSCLC), head and neck cancer and squamous urothelial carcinoma, the levels of ...

Bicara Therapeutics Inc. (BCAX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns.Don't Miss our Black Friday ...

BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung ...